Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in Japanese patients with type 2 diabetes mellitus

Journal of Clinical and Translational Endocrinology

Volumn 6, Issue , 2016, Pages 1-7

  Bando, Yukihiro ^a   Tohyama, Hitomi ^a   Aoki, Keiko ^a   Kanehara, Hideo ^a   Hisada, Azusa ^a   Okafuji, Kazuhiro ^a   Toya, Daisyu ^a  

^a FUKUI KEN SAISEIKAI HOSPITAL   (Japan)

Author keywords

Ipragliflozin; Small dense LDL cholesterol; Type 2 diabetes mellitus

Indexed keywords

EZETIMIBE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; IPRAGLIFLOZIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; JAPANESE (PEOPLE); MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PARALLEL DESIGN; PARTICLE SIZE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

EID: 84985027801     PISSN: None     EISSN: 22146237     Source Type: Journal    
DOI: 10.1016/j.jcte.2016.06.001     Document Type: Article

References (45)

1. [1] Huxley, R., Barzi, F., Woodward, M., Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 332 (2006), 73–78.
2. [2] Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35 (2012), 1364–1379.
3. [3] Ryden, L., Grant, P.J., Anker, S.D., Berne, C., Cosentino, F., Danchin, N., et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34 (2013), 3035–3087.
4. [4] Skyler, J.S., Bergenstal, R., Bonow, R.O., Buse, J., Deedwania, P., Gale, E.A., et al. Intensive glycaemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 32 (2009), 187–192.
5. [5] Bennett, W.L., Maruthur, N.M., Singh, S., Segal, J.B., Wilson, L.M., Chatterjee, R., et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 154 (2011), 602–613.
6. [6] UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998), 854–865.
7. [7] Dormandy, J.A., Charbonnel, B., Eckland, D.J., Erdmann, E., Massi-Benedetti, M., Moules, I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005), 1279–1289.
8. [8] Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A.M., et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 97 (2012), 1020–1031, 10.1210/jc.2011-2260.
9. [9] ORIGIN Trial Investigators, Mellbin, L.G., Rydén, L., Riddle, M.C., Probstfield, J., Rosenstock, J., et al. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J 34 (2013), 3137–3144.
10. [10] Komoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D., Pfister, M., Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 85 (2009), 513–519.
11. [11] Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124 (2014), 499–508.
12. [12] Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., et al. Sodiumglucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 159 (2013), 262–274.
13. [13] Kohan, D.E., Fioretto, P., Tang, W., List, J.F., Long-term study of with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85 (2014), 962–971.
14. [14] Ndrepepa, G., Braun, S., King, L., Hadamitzky, M., Haase, H.U., Birkmeier, K.A., et al. Association of uric acid with mortality in patients with stable coronary artery disease. Metabolism 61 (2012), 1780–1786.
15. [15] Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
16. [16] Monami, M., Nardini, C., Mannucci, E., Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 16 (2014), 457–466.
17. [17] Sinclair, A., Bode, B., Harris, S., Vijapurkar, U., Mayer, C., Fung, A., et al. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord, 14, 2014, 37.
18. [18] Brunzell, J.D., Davidson, M., Furberg, C.D., Goldberg, R.B., Howard, B.V., Stein, J.H., et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 51 (2008), 1512–1524.
19. [19] Björnheden, T., Babyi, A., Bondjers, G., Wiklund, O., Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 123 (1996), 43–56.
20. [20] Austin, M.A., Hokanson, J.E., Brunzell, J.D., Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance. Curr Opin Lipidol 5 (1994), 395–403.
21. [21] Feingold, K.R., Grunfeld, C., Pang, M., Doerrler, W., Krauss, R.M., LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 12 (1992), 1496–1502.
22. [22] Turner, R.C., Millns, H., Neil, H.A., Stratton, I.M., Manley, S.E., Matthews, D.R., et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ 316 (1998), 823–828.
23. [23] Washburn, W.N., Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents. Expert Opin Ther Pat 19 (2009), 1485–1499.
24. [24] Kashiwagi, A., Kazuta, K., Takinami, Y., Yoshida, S., Utsuno, A., Nagase, I., Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN study. Diabetol Int 6 (2015), 8–18.
25. [25] Hirano, T., Ito, Y., Saegusa, H., Yoshino, G., A novel and simple method for quantification of small, dense LDL. J Lipid Res 44 (2003), 2193–2201.
26. [26] Yoshino, G., Nakano, S., Matsumoto, T., Murakami, E., Morita, T., Kuboki, K., Rosuvastatin reduces plasma small dense LDL-cholesterol predominantly in non-diabetic hypercholesterolemic patients. Pharmacol Pharm 3 (2012), 72–78.
27. [27] Friedewald, W.T., Levy, R.I., Fredrickson, D.S., Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972), 499–502.
28. [28] Matsuo, S., Imai, E., Horio, M., Yasuda, Y., Tomita, K., Nitta, K., et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53 (2009), 982–992.
29. [29] Nakano, T., Inoue, I., Seo, M., Takahashi, S., Awata, T., Komoda, T., et al. Rapid and simple profiling of lipoproteins by polyacrylamide-gel disc electrophoresis to determine the heterogeneity of low-density lipoproteins (LDLs) including small, dense LDL. Recent Pat Cardiovasc Drug Discov 4 (2009), 31–36.
30. [30] Mishima, Y., Ando, M., Kuyama, A., Ishioka, T., Kibata, M., A simple method for identifying particle size of low-density lipoprotein using PAG electrophoresis: comparison between LipoPhor and Lipoprint LDL systems. J Jpn Atherscler Soc 25 (1997), 67–70 in Japanese.
31. [31] Yoshida, A., Kodama, M., Nomura, H., Naito, M., Classification of lipoprotein profile by polyacrylamide gel disc electrophoresis. Intern Med 42 (2003), 244–249.
32. [32] Landray, M.J., Sagar, G., Muskin, J., Murray, S., Holder, R.L., Lip, G.Y., Association of atherogenic low-density lipoprotein subfractions with carotid atherosclerosis. QJM 91 (1998), 345–351.
33. [33] St-Pierre, A.C., Cantin, B., Dagenais, G.R., Mauriège, P., Bernard, P.M., Després, J.P., et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study. Arterioscler Thromb Vasc Biol 25 (2005), 553–559.
34. [34] Hirano, T., Ito, Y., Koba, S., Toyoda, M., Ikejiri, A., Saegusa, H., et al. Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler Thromb Vasc Biol 24 (2004), 558–563.
35. [35] Ensign, W., Hill, N., Heward, C.B., Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics. Clin Chem 52 (2006), 1722–1727.
36. [36] Ito, Y., Fujimura, M., Ohta, M., Hirano, T., Development of a homogeneous assay for measurement of small dense LDL cholesterol. Clin Chem 57 (2011), 57–65.
37. [37] Griffin, B.A., Packard, C.J., Metabolism of VLDL and LDL subclasses. Curr Opin Lipidol 5 (1994), 200–206.
38. [38] Griffin, B.A., Low-density lipoprotein subclasses: mechanisms of formation and modulation. Proc Nutr Soc 56 (1997), 693–702.
39. [39] Nicholls, S.J., Ballantyne, C.M., Barter, P.J., Chapman, M.J., Erbel, R.M., Libby, P., et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 365 (2011), 2078–2087.
40. [40] Mikhail, N., Safety of canagliflozin in patients with type 2 diabetes. Curr Drug Saf 9 (2014), 127–132.
41. [41] Inagaki, N., Goda, M., Yokota, S., Maruyama, N., Iijima, H., Effects of baseline blood pressure and low-density lipoprotein cholesterol on safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus. Adv Ther 32 (2015), 1085–1103.
42. [42] Shigematsu, E., Yamakawa, T., Kadonosono, K., Terauchi, Y., Effect of sitagliptin on lipid profile in patients with type 2 diabetes mellitus. J Clin Med Res 6 (2014), 327–335.
43. [43] Kashiwagi, A., Kazuta, K., Goto, K., Yoshida, S., Ueyama, E., Utsuno, A., Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 17 (2015), 304–308.
44. [44] Bando, Y., Toyama, H., Kanehara, H., Hisada, A., Okafuji, K., Toya, D., et al. Switching from atorvastatin to rosuvastatin lowers small, dense low-density lipoprotein cholesterol levels in Japanese hypercholesterolemic patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 111 (2016), 66–73.
45. [45] Hayashi, T., Hirano, T., Yamamoto, T., Ito, Y., Adachi, M., Intensive insulin therapy reduces small dense low-density lipoprotein particles in patients with type 2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies. Metabolism 55 (2006), 879–884.